Compare TDY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDY | RPRX |
|---|---|---|
| Founded | 1960 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4B | 25.9B |
| IPO Year | 2000 | 2020 |
| Metric | TDY | RPRX |
|---|---|---|
| Price | $679.67 | $58.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $693.71 | $51.40 |
| AVG Volume (30 Days) | 412.1K | ★ 2.9M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 9.70 | N/A |
| EPS | ★ 10.20 | 0.71 |
| Revenue | $1,020,400,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $5.54 | $38.63 |
| Revenue Next Year | $5.08 | $4.73 |
| P/E Ratio | ★ $66.04 | $82.46 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $483.02 | $34.63 |
| 52 Week High | $697.67 | $60.44 |
| Indicator | TDY | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 54.66 |
| Support Level | $627.29 | $55.66 |
| Resistance Level | $690.19 | $58.84 |
| Average True Range (ATR) | 14.65 | 1.43 |
| MACD | 0.46 | -0.07 |
| Stochastic Oscillator | 72.35 | 53.43 |
Teledyne Technologies Inc provides enabling technologies to sense, analyze and distribute information for industrial growth markets that require advanced technology and high reliability. The firm operates in four segments: Digital Imaging, Instrumentation, Aerospace and Defense Electronics, and Engineered Systems. The Digital Imaging segment, that derives maximum revenue, includes high-performance sensors, cameras and systems, within the visible, infrared and X-ray spectra for use in industrial, government and medical applications, as well as MEMS and high-performance, high-reliability semiconductors including analog-to-digital and digital-to-analog converters. Geographically, the company operates in United States, Europe, Asia, and All other.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.